Net Asset Value(s)

RNS Number : 9138E

Port Erin Biopharma Investments Ltd

22 July 2016

 

22 July 2016

Port Erin Biopharma Investments Limited

(the "Company")

Net Asset Value calculation to 30 June 2016

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2016 was 9.28 pence per share, including un-invested cash of £11,985.  The portfolio is valued under IFRS at bid price.

Net Assets stand at £2.2 million including Investments of £2.19 million.  This quarter's NAV represents a decrease of 9.11% from the previous valuation of 10.21 pence per share, which included un-invested cash of £10,713.  No additional management fee is due to Shellbay Investments Limited.

		Unaudited to 30 June 2016    £
Fixed Assets
	Investments	2,187,075
Current Assets
	Sundry Debtors	7,335
	Uninvested cash	11,985
Current Liabilities
	Creditors: amounts due	(54,197)
		2,152,198
Capital and Reserves
	Share Capital	23
	Share Premium	1,890,142
	Reserves	262,033
		2,152,198
Shares in Issue		23,195,558
Net Asset Value per share		9.28 pence

Portfolio Details

Investments as at 30 June 2016	Value	% of Total Portfolio
Magna Biopharma Income Fund	£1,231,912	56.3%
Regent Pacific Group	£249,594	11.4%
Summit Corporation	£218,291	10.0%
Other quoted holdings	£85,407	3.9%
Other unquoted holdings	£401,871	18.4%
Total	£2,187,075	100.0%

For further information, please contact:

Port Erin Biopharma Investments Limited	Northland Capital Partners Limited	Peterhouse Capital Limited
The Company	Nomad and Broker	Joint Broker
Denham Eke (+44) (0) 1624 639396	Matthew Johnson / David Hignell (+44) (0) 203 861 6625	Lucy Williams (+44) (0) 207 469 0936

 

END

 

 

NAVFMGZNKMMGVZM